Informe de análisis del tamaño, la participación y las tendencias del mercado global de fabricación de API por contrato de terapias peptídicas: descripción general del sector y pronóstico hasta 2032

Tamaño del mercado de fabricación de API por contrato de terapias peptídicas

• El tamaño del mercado global de fabricación de API por contrato de terapias peptídicas se valoró en USD 3.48 mil millones en 2024 y se espera que alcance los USD 6.16 mil millones para 2032 , con una CAGR del 9,00% durante el período de pronóstico.
• Este crecimiento está impulsado por factores como la creciente prevalencia de enfermedades crónicas , los avances en las tecnologías de síntesis de péptidos y la expansión de la investigación y el desarrollo biofarmacéutico.

Análisis del mercado de fabricación por contrato de API de péptidos terapéuticos

• La fabricación por contrato de API para terapias peptídicas implica la externalización de la producción de principios activos farmacéuticos (API) para fármacos basados ​​en péptidos. Este enfoque permite a las compañías farmacéuticas aprovechar la experiencia y las instalaciones especializadas, garantizando procesos de fabricación eficientes y rentables.
• El crecimiento del mercado se ve impulsado significativamente por la creciente adopción de terapias basadas en péptidos, los avances en la tecnología de síntesis y la tendencia a externalizar la fabricación farmacéutica a fabricantes especializados de API. Los péptidos están ganando terreno en la investigación farmacéutica gracias a su alta especificidad, baja toxicidad y un índice terapéutico favorable.
• Se espera que América del Norte domine el mercado de fabricación de API por contrato de terapias peptídicas con una participación del 40,3%, impulsada por una sólida industria farmacéutica, una infraestructura de atención médica avanzada e inversiones significativas en biotecnología.
• Se espera que Asia-Pacífico sea la región de más rápido crecimiento en el mercado de fabricación de API por contrato de terapias peptídicas con una participación del 23,6%, impulsada por el rápido desarrollo de la infraestructura de atención médica, la creciente demanda de terapias innovadoras y políticas gubernamentales de apoyo.
• Se prevé que el segmento de síntesis química domine el mercado con una cuota de mercado del 41,8 %, gracias a la alta eficiencia y escalabilidad del SPPS. Este método permite la producción automatizada y gradual de péptidos de alta pureza y facilita la fabricación a gran escala, lo que contribuye a su adopción generalizada en la producción de péptidos terapéuticos.

Alcance del informe y segmentación del mercado de fabricación de API por contrato de terapias peptídicas 

Tendencias del mercado de fabricación de API por contrato de péptidos terapéuticos

Avances en la fabricación de API de péptidos y tendencias de subcontratación

• Una tendencia destacada en la fabricación de API de péptidos es la creciente adopción de tecnologías de síntesis avanzadas, como la síntesis de péptidos en fase sólida (SPPS), la síntesis de péptidos en fase líquida (LPPS) y las técnicas asistidas por microondas. Estas innovaciones mejoran la eficiencia de la producción, reducen los costos y permiten la síntesis de estructuras peptídicas complejas, mejorando así la escalabilidad y el control de calidad.
• La creciente demanda de agonistas del receptor GLP-1, impulsada por la creciente prevalencia de la diabetes tipo 2 y la obesidad, está impactando significativamente el mercado de API de péptidos. Las compañías farmacéuticas están invirtiendo fuertemente en la expansión de su capacidad de fabricación para satisfacer esta demanda.
  • For instance, Eli Lilly has committed an additional USD 5.3 billion to a new Indiana manufacturing site to boost production of its diabetes and weight loss drugs, Mounjaro and Zepbound
• Outsourcing peptide API manufacturing to Contract Manufacturing Organizations (CMOs) is becoming increasingly prevalent, especially in regions such as Asia-Pacific. Countries such as India and China offer cost-effective production facilities, making them attractive destinations for pharmaceutical companies seeking to reduce expenses and enhance efficiency
• The integration of green chemistry and sustainable manufacturing processes is gaining traction in the peptide API industry. Companies are exploring environmentally friendly methods, including the use of recombinant DNA technology, to minimize chemical byproducts and reduce environmental impact

Peptide Therapeutics Contract API Manufacturing Market Dynamics

Driver

“Increasing Demand for Peptide-Based Therapies”

• The growing demand for peptide-based therapeutics in the treatment of various chronic and complex diseases, such as cancer, diabetes, and autoimmune disorders, is driving the need for peptide therapeutics contract API manufacturing services
•  Peptides are becoming increasingly favoured due to their specificity and potency, offering targeted therapies with fewer side effects compared to traditional small-molecule drugs
• The global rise in chronic diseases, along with the expanding pipeline of peptide-based drug candidates, is leading to increased demand for efficient, scalable peptide production

For instance,

• In November 2023, a report published by the World Health Organization (WHO) projected those chronic diseases such as cancer and diabetes would continue to rise globally, with cancer alone accounting for over 16 million new cases by 2040. This presents an increased need for peptide-based treatments that offer precision targeting for such diseases 
• As the demand for peptides grows, there is a greater need for specialized contract API manufacturers that can meet the high standards of peptide production and deliver cost-effective, scalable solutions to pharmaceutical companies

Opportunity

“Advancements in Peptide Synthesis and Production Technologies”

• The development of more advanced peptide synthesis technologies, such as solid-phase peptide synthesis (SPPS) and recombinant DNA technology, is enabling more efficient and cost-effective production of peptides
• Contract API manufacturers can leverage these new technologies to scale up production while maintaining high purity and quality, meeting the increasing demand for therapeutic peptides
• Innovations in automation and continuous manufacturing techniques are expected to further reduce costs and production timelines, opening up opportunities for the wider adoption of peptide-based therapies

For instance,

• In January 2025, a study published in Nature Biotechnology highlighted advancements in continuous-flow peptide synthesis, which allows for faster and more efficient production of peptides. The study suggested that the application of these technologies could help meet the growing demand for peptides in the pharmaceutical industry while reducing manufacturing costs and time to market 
• These advancements will not only lower production costs but also enhance the scalability and flexibility of contract manufacturers, creating significant opportunities in the peptide therapeutics market

Restraint/Challenge

“High Production Costs and Complex Manufacturing Processes”

• The production of peptides involves complex and time-consuming processes, such as solid-phase peptide synthesis, purification, and quality control, leading to high manufacturing costs
• Peptide API production requires specialized facilities and expertise, adding to the overall cost of manufacturing. This can present a barrier to entry for smaller contract manufacturers or pharmaceutical companies with limited budgets

For instance,

• In October 2024, a report from the International Society for Pharmaceutical Engineering (ISPE) emphasized the challenges faced by contract peptide manufacturers in managing the high costs associated with the production of therapeutic peptides. These costs can be attributed to the specialized equipment required, the complexity of synthesis processes, and the stringent regulatory requirements 
• As a result, these challenges can limit the affordability of peptide therapeutics, particularly for smaller pharmaceutical companies and healthcare systems in emerging markets, slowing down the overall market growth

Peptide Therapeutics Contract API Manufacturing Market Scope

The market is segmented on the basis of scale of operation, synthesis method and enterprise type.

In 2025, the chemical synthesis is projected to dominate the market with a largest share in synthesis method segment

The chemical synthesis segment, is expected to dominate the peptide therapeutics contract API manufacturing market with the largest share of approximately 41.8% in 2025. This dominance is attributed to the high efficiency and scalability of SPPS, which enables automated, stepwise peptide production with high purity. The method's ability to support large-scale manufacturing and its widespread adoption in therapeutic peptide production further contribute to its market leadership.

The large enterprise is expected to account for the largest share during the forecast period in enterprise type market

In 2025, the large enterprises segment is expected to dominate the peptide therapeutics contract API manufacturing market, accounting for over 40.6% of the global installed peptide manufacturing capacity. This dominance is driven by their extensive resources, advanced technologies, and established infrastructures, which enable them to meet the complex requirements of peptide API manufacturing. Their ability to support efficient production, comply with stringent regulatory standards, and manage large-scale operations further solidifies their leadership in the market.

Peptide Therapeutics Contract API Manufacturing Market Regional Analysis

“North America Holds the Largest Share in the Peptide Therapeutics Contract API Manufacturing Market”

• North America dominates the peptide therapeutics contract API manufacturing market with share of 40.3%, driven by a strong pharmaceutical industry advanced healthcare infrastructure, and significant investments in biotechnology
• U.S. holds a 30.9% share of the market, supported by a high demand for innovative peptide-based therapies for chronic diseases such as cancer, diabetes, and cardiovascular disorders
• The region's well-established regulatory framework, coupled with the presence of major contract manufacturers and extensive research and development activities, further strengthens its market position
• In addition, the rising prevalence of chronic diseases and the growing focus on precision medicine and biologics are fueling the demand for peptide therapeutics, contributing to market expansion

“Asia-Pacific is Projected to Register the Highest CAGR in the Peptide Therapeutics Contract API Manufacturing Market”

• Asia-Pacific is expected to witness the highest growth rate in the peptide therapeutics contract API manufacturing market with a share of 23.6%, driven by rapid healthcare infrastructure development, increasing demand for innovative therapies, and supportive government policies
• Countries such as China, India, and South Korea are emerging as major markets due to their expanding pharmaceutical manufacturing capabilities, cost-effective production, and growing biotech sectors
• China, with its large patient population and government support for biotech innovation, remains a critical market for peptide therapeutics, attracting significant foreign investments
• India is projected to register the highest CAGR of 6.3% in the market, supported by a growing pharmaceutical industry, increasing focus on biopharmaceuticals, and a rapidly expanding contract manufacturing sector

Peptide Therapeutics Contract API Manufacturing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Bachem Group (Switzerland)
• CordenPharma (Germany)
• Lonza (Switzerland)
• PolyPeptide Group (Sweden)
• AmbioPharm Inc. (U.S.) 
• WuXi AppTec (China)
• CEM Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• JITSUBO CO,LTD. (Japan)
• ChemPartner (China)
• ApexBio Technology (U.S.)
• Biotage (Sweden)
• AnaSpec (U.S.)
• Syngene International Limited (India)
• BCNPeptides (Spain)
• CPC Scientific Inc. (U.S.)
• Creative Peptides (U.S.)
• CSBio (U.S.)
• Hybio Pharmaceutical Co., Ltd. (U.S.)
• Senn Chemicals (Switzerland)

Latest Developments in Global Peptide Therapeutics Contract API Manufacturing Market

• In January 2025, Bachem Holding AG, a leading peptide manufacturer, announced the expansion of its manufacturing capacity in Switzerland, aiming to meet the growing global demand for peptide APIs. The new facility will include advanced solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) capabilities, enabling the production of highly complex peptides with improved scalability and efficiency. The investment also focuses on integrating cutting-edge purification technologies to ensure high-quality peptide APIs for pharmaceutical applications
• In October 2024, Lonza Group AG announced the completion of its peptide manufacturing facility expansion in Visp, Switzerland. The facility now features state-of-the-art production technologies, including continuous flow manufacturing, which significantly reduces production time and cost. This strategic move strengthens Lonza's position as a key player in the global peptide API market, supporting the growing demand for personalized medicine and biologics
• In September 2024, Polypeptide Group unveiled a new, fully automated peptide synthesis platform at its Malmö, Sweden, facility. This platform leverages advanced automation and AI-driven process control to enhance efficiency, reduce batch-to-batch variability, and optimize production costs. The company also announced plans to invest in downstream processing capabilities to improve peptide purification and scalability
• In September 2024, AmbioPharm Inc. launched a new state-of-the-art manufacturing facility in South Carolina, U.S., focused on the production of high-purity peptide APIs for clinical and commercial applications. The facility includes cutting-edge SPPS and purification technologies, designed to support the increasing demand for complex peptide therapeutics in the global market
• In August 2024, WuXi AppTec announced the expansion of its peptide manufacturing capabilities at its Changzhou, China, site. The expansion includes the addition of large-scale reactors, advanced analytical testing facilities, and a fully integrated quality control system, enhancing its ability to deliver high-quality peptide APIs for pharmaceutical clients worldwide

SKU-73998